At present, the clinical treatments for NSCLC include surgery, chemotherapy (such as mitomycin, gemcitabine, ifosfamide, and cisplatin), immunotherapy (including durvalumab), targeted therapy (e.g., EGFR inhibitors, vascular endothelial growth factor [VEGF] receptor inhibitors, and ALK inhibitors), and combined therapy [6]. This evidence concerns the gene ALK and non-small cell lung carcinoma.